Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Market Closed 07-24 16:00:00 EDT

4.32

-0.07

-1.59%

盘后4.26

-0.06-1.39%

19:34 EDT

High4.42	Low4.29	Vol465.32K
Open4.42	D1 Closing4.39	Amplitude2.96%
Mkt Cap278.94M	Tradable Cap213.56M	Total Shares64.57M
T/O2.01M	T/O Rate0.94%	Tradable Shares49.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":4.32,"timestamp":1784923200000,"preClose":4.39,"halted":0,"volume":465316,"hourTrading":{"tag":"盘后","latestPrice":4.26,"preClose":4.32,"latestTime":"19:34 EDT","volume":15834,"amount":68395.9801,"timestamp":1784936045399,"change":-0.06,"changeRate":-0.013889,"amplitude":0.018519},"delay":0,"changeRate":-0.015945330296127425,"floatShares":49435000,"shares":64569967,"eps":-1.06,"marketStatus":"Market Closed","change":-0.07,"latestTime":"07-24 16:00:00 EDT","open":4.42,"high":4.42,"low":4.29,"amount":2010475.951088,"amplitude":0.029613,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.06,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":4.39,"preHourTrading":{"tag":"盘前","latestPrice":4.407,"preClose":4.39,"latestTime":"07:44 EDT","volume":112,"amount":493.379992,"timestamp":1784893453583,"change":0.017,"changeRate":0.003872,"amplitude":0.003872},"postHourTrading":{"tag":"盘后","latestPrice":4.26,"preClose":4.32,"latestTime":"19:34 EDT","volume":15834,"amount":68395.9801,"timestamp":1784936045399,"change":-0.06,"changeRate":-0.013889,"amplitude":0.018519},"volumeRatio":0.512688296014038,"impliedVol":2.3925,"impliedVolPercentile":0.931},"requestUrl":"/m/hq/s/IMRX/wiki","defaultTab":"wiki","newsList":[{"id":"2653785250","title":"Immuneering publishes preclinical data on atebimetinib in Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785250?lang=en_us&edition=fundamental","pubTime":"2026-07-22 05:10","pubTimestamp":1784668216,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX) announced the publication of new findings in Cancer Research, a journal of the American Association for Cancer Research, charact...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-publishes-preclinical-data-on-atebimetinib-in-cancer-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-publishes-preclinical-data-on-atebimetinib-in-cancer-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653788984","title":"Immuneering Flags New Press Release on Atebimetinib Preclinical Study Publication in Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2653788984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653788984?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:10","pubTimestamp":1784664623,"startTime":"0","endTime":"0","summary":"Immuneering flags new press release on atebimetinib preclinical study publication in Cancer ResearchImmuneering disclosed aCancer Researchpublication on atebimetinib showing broad, durable preclinical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL1Pjzrl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","IMRX","SG9999014021.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","IE00BN0W2V16.EUR","LU0314104364.USD","NDAQ","BCDF","SG9999014013.SGD","BK4585","BK4563","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297568","title":"Immuneering Corp : Needham Raises Target Price to $18 from $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297568?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:46","pubTimestamp":1784544415,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M0PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297552","title":"Immuneering is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297552","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297552?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:42","pubTimestamp":1784544120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings(END) Dow Jones NewswiresJuly 20, 2026 06:42 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652028071","title":"Immuneering Corporation Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2652028071","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652028071?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:05","pubTimestamp":1784318700,"startTime":"0","endTime":"0","summary":"NEW YORK, July  17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329277/0/en/Immuneering-Corporation-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMRX","BK4563","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652424753","title":"Immuneering CFO Andrew Gengos Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2652424753","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652424753?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:11","pubTimestamp":1784232675,"startTime":"0","endTime":"0","summary":"Immuneering CFO Andrew Gengos files initial beneficial ownership statementImmuneering CFO Andrew Gengos filed an initial Form 3 showing direct ownership of 225,000 shares of Class A common stock as of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL5zWc7J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","IMRX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651100961","title":"Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651100961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651100961?lang=en_us&edition=fundamental","pubTime":"2026-07-13 23:00","pubTimestamp":1783954842,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX), Vera Therapeutics (VERA) and A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-vera-therapeutics-vera-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-vera-therapeutics-vera-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4539","BK4548","LABU","LU0320765992.SGD","IMRX","LU2324357040.USD","BK4563","ALNY","LU0114720955.EUR","BK4139","BK4588","LU0109394709.USD","VERA","LU0128526141.USD","XLV","LU0882574055.USD","PBE","LU0889565916.HKD","HCSG","XBI","BK4585","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999965","title":"Immuneering Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999965?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:27","pubTimestamp":1783517220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 09:27 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649998809","title":"Immuneering initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649998809?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:55","pubTimestamp":1783508140,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Li Watsek initiated coverage of Immuneering (IMRX) with an Overweight rating and $17 price target Immuneering is developi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649367911","title":"Kalaris Appoints Laurie Keating to Board, Replacing Morana Jovan-embiricos","url":"https://stock-news.laohu8.com/highlight/detail?id=2649367911","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649367911?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:06","pubTimestamp":1783368368,"startTime":"0","endTime":"0","summary":"Kalaris appoints Laurie Keating to board, replacing Morana Jovan-EmbiricosKalaris Therapeutics named Laurie Keating to its board, effective Aug. 1, 2026.Director Morana Jovan-Embiricos will step down ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL5PG1ny:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","LU0109394709.USD","LU0889565916.HKD","IE00B64PRP62.GBP","BK4139","BCDF","LU0320765992.SGD","IMRX","LU0882574055.USD","SG9999014005.SGD","BK4588","KLRS","ALNY","IE00BN0W2V16.EUR","BK4539","NDAQ","LU2210150020.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","PBE","SG9999014021.USD","BK4563","SG9999014039.USD","LU0114720955.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","BK4548","LU2095319765.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646823899","title":"Top Executive Makes Bold Insider Move on Immuneering Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2646823899","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646823899?lang=en_us&edition=fundamental","pubTime":"2026-06-25 10:03","pubTimestamp":1782353022,"startTime":"0","endTime":"0","summary":"New insider activity at Immuneering ( ($IMRX) ) has taken place on June 24, 2026. Immuneering’s President and CEO, Benjamin J. Zeskind, has increas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-bold-insider-move-on-immuneering-stock-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-bold-insider-move-on-immuneering-stock-insider-trading-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646284550","title":"Immuneering CEO Benjamin Zeskind Acquires 2,400 Shares for $10,948.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2646284550","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646284550?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:12","pubTimestamp":1782331939,"startTime":"0","endTime":"0","summary":"Immuneering CEO Benjamin Zeskind acquires 2,400 shares for $10,948.08Immuneering President and CEO Benjamin J. Zeskind bought 2,400 shares of Class A common stock at USD 4.56.Direct holdings rose to 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDLbyfC4p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immuneering CEO Benjamin Zeskind Acquires 2,400 Shares for $10,948.08","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644876760","title":"Immuneering Chief Scientific Officer Brett Matthew Hall buys $25,045 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644876760","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644876760?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:16","pubTimestamp":1781640968,"startTime":"0","endTime":"0","summary":"Immuneering Chief Scientific Officer Brett Matthew Hall bought 6,035 shares of Class A common stock at USD 4.15.Direct ownership rose to 382,531 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL9nPHWb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immuneering Chief Scientific Officer Brett Matthew Hall buys $25,045 of common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IMRX","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644461764","title":"Mizuho Securities Reaffirms Their Buy Rating on Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644461764","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644461764?lang=en_us&edition=fundamental","pubTime":"2026-06-17 02:15","pubTimestamp":1781633717,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Immuneering today and set a price target of $12.00. Suvannavejh covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643178655","title":"Immuneering Appoints Veteran Biotech Leader as New CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643178655","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643178655?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:35","pubTimestamp":1781555732,"startTime":"0","endTime":"0","summary":"An update from Immuneering ( ($IMRX) ) is now available. On June 11, 2026, Immuneering Corporation’s board appointed veteran biotech executive Andr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immuneering-appoints-veteran-biotech-leader-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immuneering-appoints-veteran-biotech-leader-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","BK4139","BK4539","BK4585","IMRX","BK4581","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643205782","title":"Immuneering Names Andrew Gengos as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205782","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643205782?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:58","pubTimestamp":1781528307,"startTime":"0","endTime":"0","summary":"Immuneering  has named Andrew Gengos as chief financial officer, starting July 16, the company said Monday.Gengos most recently served as CFO and head of corporate development at Terns Pharmaceuticals, the company said.He previously served as CFO and chief business officer of Athira Pharma, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643082002","title":"Immuneering Names Andrew Gengos Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643082002","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643082002?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:53","pubTimestamp":1781524380,"startTime":"0","endTime":"0","summary":"Immuneering has hired Andrew Gengos as the late-stage clinical oncology company's new chief financial officer.Immuneering on Monday said Gengos most recently served as finance chief and head of corporate development at Terns Pharmaceuticals, which Merck & Co. acquired last month.Mallory Morales, Immuneering's senior vice president of finance, chief accounting officer and treasurer, has been serving as the Cambridge, Mass., company's principal financial and accounting officer.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643083122","title":"Immuneering - Appoints Andrew Gengos as Chief Financial Officer Effective July 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643083122","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643083122?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA5VT9QB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMRX","BK4139","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643520833","title":"Press Release: Immuneering Appoints Andrew Gengos as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643520833","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643520833?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523000,"startTime":"0","endTime":"0","summary":"- Former CFO of Terns Pharmaceuticals to join Immuneering -. \"Andrew is a proven biotechnology executive with a strong track record of helping innovative companies navigate critical stages of growth and value creation,\" said Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. \"His experience as a CFO, business development leader, and strategic advisor will be invaluable as we advance our clinical programs and prepare for the next phase of Immuneering's growth. We are delighted to welcome Andrew to our leadership team.\". \"I am thrilled to join Immuneering at such an exciting time in the company's development,\" said Andrew Gengos. \"Atebimetinib is now a Phase 3 candidate in first-line pancreatic cancer, supported by recently presented survival and tolerability data that are highly encouraging in a disease where new treatment options are urgently needed. A growing body of data supports the potential of Immuneering's differentiated deep cyclic inhibitor technology to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423703","title":"Immuneering Shareholders Approve Directors and Auditor at Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423703","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423703?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:58","pubTimestamp":1781218732,"startTime":"0","endTime":"0","summary":"Immuneering ( ($IMRX) ) has shared an update. Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, with 44,495,059 Cla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immuneering-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immuneering-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4563","IMRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.069},{"period":"1month","weight":-0.0609},{"period":"3month","weight":-0.2848},{"period":"6month","weight":-0.194},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.3435}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.4,"avgChangeRate":0.059054},{"month":4,"riseRate":0.2,"avgChangeRate":-0.166499},{"month":5,"riseRate":0.4,"avgChangeRate":0.024846},{"month":6,"riseRate":0.6,"avgChangeRate":0.254483},{"month":7,"riseRate":0.6,"avgChangeRate":-0.004707},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}